Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 45

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 45
---
514,279 |     |              | — |     |           | 546,806 |
| Robert More                           |     |             | 83,833 |     |            | — |     |         | 221,855 |     |              | — |     |           | 305,689 |
| S. Michael Rothenberg, M.D., Ph.D.(5) |     |             | 29,274 |     |            | — |     |         | 514,279 |     |              | — |     |           | 543,553 |
| Jake Simson, Ph.D.                    |     |             | 52,333 |     |            | — |     |         | 221,855 |     |              | — |     |           | 274,189 |
| Siddarth Subramony, Ph.D. (6)         |     |             | 34,987 |     |            | — |     |         | 221,855 |     |              | — |     |           | 256,842 |
| Rehan Verjee                          |     |             | 53,333 |     |            | — |     |         | 221,855 |     |              | — |     |           | 275,189 |

| (1) | The amounts reported represent the aggregate grant date fair value of the stock options awarded to the non-employee director during fiscal year 2024, calculated in accordance with FASB ASC Topic 718. Such grant date fair value does not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in Note 7 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 27, 2025. The amounts reported in this column reflect the accounting cost for the stock options and do not reflect the actual economic value that will be realized upon the vesting of the stock options, the exercise of the stock options or the sale of the Common Stock underlying such awards. |

| (2) | Dr. Chen resigned from our Board on May 4, 2024. |

| (3) | Ms. Kjellson resigned from our Board on January 29, 2025. |

| (4) | Dr. McCracken has waived her right to receive compensation under our non-employee